The Obsessive-Compulsive Disorder drugs in development market research report provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Obsessive-Compulsive Disorder. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Obsessive-Compulsive Disorder by 11 companies/universities/institutes. The top development phase for Obsessive-Compulsive Disorder is preclinical with four drugs in that stage. The Obsessive-Compulsive Disorder pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Obsessive-Compulsive Disorder pipeline products market are: Biogen, Omeros and Alira Health.
The key targets in the Obsessive-Compulsive Disorder pipeline products market include 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, and B Lymphocyte Antigen CD20.
The key mechanisms of action in the Obsessive-Compulsive Disorder pipeline product include 5-Hydroxytryptamine Receptor 1A Agonist with five drugs in Phase II. The Obsessive-Compulsive Disorder pipeline products include four routes of administration with the top ROA being Oral and two key molecule types in the Obsessive-Compulsive Disorder pipeline products market including Small Molecule, and Monoclonal Antibody.
Obsessive-Compulsive Disorder overview
Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead the patient to perform repetitive behaviors (compulsions). Symptoms include having repeated thoughts or mental images about certain things, such as fears of germs, dirt, intruders, acts of violence, or hurting loved ones; and doing the same rituals over and over, such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Risk factors include family history. Treatment includes antidepressants and psychiatric medications.
For a complete picture of Obsessive-Compulsive Disorder’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
